Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Table 3 Study subject end of treatment objective response rates

Utidelone starting dose, mg/m²	Best response,^a n						ORR,^b %
	CR	PR	SD	PD	NA	Total	ORR	95 % CI^c
Combination therapy: utidelone (30 mg/m²) and capecitabine (2000 mg/m²) n = 33
25	0	2	1	0	0	3	66.7	9.4, 99.2
30	1	11	10	2	1	25	48.0	27.8, 68.7
35	0	0	4	1	0	5	0	–
Total	1	13	15	3	0	33	42.4	26.6, 60.9
Monotherapy: utidelone (40 mg/m²) n = 70
40	1	19^d	25	18	7	70	28.57	18.40, 40.62

CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, CI confidence interval
^aAssessed according to RECIST1.1
^bORR = (CR + PR)/total × 100 %
^cCalculated using Clopper Pearson method
^dIncluding 17 patients with PR and 2 patients with unconfirmed PR

ISSN: 1756-8722